World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
38782
World Ranking
8875
National Ranking
498

Hans-Joachim Schmoll publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hans-Joachim Schmoll sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 627 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hans-Joachim Schmoll D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hans-Joachim Schmoll sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Hans-Joachim Schmoll is affiliated with Martin Luther University Halle-Wittenberg in Germany. Their research primarily focuses on medicine, with a significant emphasis on oncology. Within this field, they have contributed extensively to subfields such as oncology, pulmonary and respiratory medicine, pathology and forensic medicine, hepatology, and surgery.

The scientist's work addresses multiple topics relevant to cancer treatment and management. Key areas of research include colorectal cancer treatments and studies, colorectal cancer surgical treatments, gastric cancer management and outcomes, genetic factors in colorectal cancer, hepatocellular carcinoma treatment and prognosis, cancer treatment and pharmacology, and colorectal cancer screening and detection.

Hans-Joachim Schmoll's publications have appeared in several scientific journals. Frequent venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • JNCI Journal of the National Cancer Institute
  • European Journal of Cancer
  • ESMO Open

Recent notable papers authored or co-authored by Schmoll cover various oncological topics:

  • Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD (2020, Journal of Clinical Oncology)
  • Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer (2020, Journal of Clinical Oncology)
  • Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022, Leukemia)
  • MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer (2022, ESMO Open)
  • Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database (2021, JNCI Journal of the National Cancer Institute)

Hans-Joachim Schmoll collaborates with several researchers, among the most frequent co-authors are:

  • Aimery de Gramont
  • Qian Shi
  • Eric Van Cutsem
  • Richard M. Goldberg
  • Takayuki Yoshino

Best Publications

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment

    Axel Grothey;Daniel Sargent;Richard M. Goldberg;Hans Joachim Schmoll

  • Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

    Daniel G. Haller;Josep Tabernero;Jean Maroun;Filippo De Braud

  • European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I

    Susanne Krege;Jörg Beyer;Rainer Souchon;Peter Albers

  • Cyclooxygenase-2: a novel target for cancer chemotherapy?

    Wolfram Dempke;Christoph Rie;Axel Grothey;Hans Joachim Schmoll

  • European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

    H. J. Schmoll;R. Souchon;S. Krege;P. Albers

  • Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    Aimery de Gramont;Eric Van Cutsem;Hans Joachim Schmoll;Josep Tabernero

  • Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

    Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni

  • Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum: Results From an International Analysis

    Carsten Bokemeyer;Craig R. Nichols;Jean P. Droz;Hans J. Schmoll

  • Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials

    Cornelis J A Punt;Marc Buyse;Claus Henning Köhne;Peter Hohenberger

  • Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

    Hans Joachim Schmoll;Thomas Cartwright;Josep Tabernero;Marek P. Nowacki

  • Multidisciplinary Rectal Cancer Management : 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)

    Vincenzo Valentini;Cynthia Aristei;Bengt Glimelius;Bruce D. Minsky

  • Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer

    C Bokemeyer;CC Berger;JT Hartmann;C Kollmannsberger

  • High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

    J Beyer;A Kramar;R Mandanas;W Linkesch

  • [Update S3-guideline "colorectal cancer" 2008].

    W. Schmiegel;A. Reinacher-Schick;D. Arnold;U. Graeven

  • Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

    Rainer Porschen;Hendrik Tobias Arkenau;Stephan Kubicka;Richard Greil

  • Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    Andres J. M. Ferreri;Kate Cwynarski;Elisa Pulczynski;Christopher P. Fox

  • Evaluation of long-term toxicity after chemotherapy for testicular cancer.

    C Bokemeyer;C C Berger;M A Kuczyk;H J Schmoll

  • Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer

    Claus Rödel;Gerhard. G. Grabenbauer;Thomas Papadopoulos;Werner Hohenberger

Frequent Co-Authors

Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Carsten Bokemeyer
Carsten Bokemeyer Universität Hamburg
Aimery de Gramont
Aimery de Gramont Grenoble Alpes University
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Daniel G. Haller
Daniel G. Haller University of Pennsylvania
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
John R. Zalcberg
John R. Zalcberg Monash University
Alfredo Falcone
Alfredo Falcone University of Pisa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA opens a variety of educational routes, many of which can be pursued online. For those interested in healthcare management, earning a health care administration degree can be a strategic move. These programs are often offered in an accelerated format, enabling students to quickly advance into roles managing hospitals or clinics.

Nursing remains a popular and flexible path. Some nursing schools that don't require teas test simplify the admissions process for aspiring nurses, creating a smoother entry into the profession. Already an RN? Bridge programs such as the rn to np bridge program allow registered nurses to become nurse practitioners efficiently, expanding both career scope and earning potential.

For those who prefer an administrative role, reputable medical billing and coding online schools offer foundational training with flexible schedules—often with financial aid—making this career accessible to more students. Whether you choose patient care or the administrative side of medicine, online pathways can help you reach your goals more efficiently.

Best Scientists Citing Hans-Joachim Schmoll

Trending Scientists

Recently Published Articles